TY - JOUR
T1 - Supporting new vaccine introduction decisions
T2 - Lessons learned from the Hib Initiative experience
AU - hajjeh, R
AU - Privor-Dumm, L
AU - Edmond, Karen
AU - O'Loughlin, Rosalyn
AU - Shetty, Sharmila
AU - Griffiths, Ulla K
AU - Bear, A P
AU - Cohen, Adam
AU - Chandran, A
AU - Schuchat, A
AU - MULHOLLAND, Edward (Kim)
AU - Santosham, M
PY - 2010/10/8
Y1 - 2010/10/8
N2 - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.
AB - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.
U2 - 10.1016/j.vaccine.2010.07.028
DO - 10.1016/j.vaccine.2010.07.028
M3 - Article
VL - 28
SP - 7123
EP - 7129
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 43
ER -